Furthermore, a remarkable study suggested that Guanabenz, an alpha-2 adrenergic agonist used to treat hypertension, might be employed as therapeutic agents to elevate parkin levels, whose reduced function appears to be a central pathogenic event in PD, consequently decelerating neurodegeneration in PD and other neurodegenerative conditions [69]. This evidence concerns the gene PSMA2 and hypertensive disorder.